STAT+: FDA approves Verastem’s ovarian cancer treatment
And more biotech news, brought to you by The Readout.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we talk about the FDA’s new artificial intelligence effort in the wake of mass layoffs, see AI darling Insitro cut staff, and more.
Questions about the FDA’s fast-tracking AI review
Calling it a “historic first,” FDA chief Marty Makary ordered every review decision at the agency to start using a new generative-AI system and hit “full implementation” by June 30, promising it will improve productivity — perhaps giving some workers a much-needed reprieve given the extent of layoffs that have hit the agency.
